|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48.
2023.PubMed/NCBI
|
|
2
|
Luo J: KRAS mutation in pancreatic cancer.
Semin Oncol. 48:10–18. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stickler S, Rath B and Hamilton G:
Targeting KRAS in pancreatic cancer. Oncol Res. 32:799–805. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dilly J, Hoffman MT, Abbassi L, Li Z,
Paradiso F, Parent BD, Hennessey CJ, Jordan AC, Morgado M, Dasgupta
S, et al: Mechanisms of resistance to oncogenic KRAS inhibition in
pancreatic cancer. Cancer Discov. 14:2135–2161. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Varghese AM, Perry MA, Chou JF, Nandakumar
S, Muldoon D, Erakky A, Zucker A, Fong C, Mehine M, Nguyen B, et
al: Clinicogenomic landscape of pancreatic adenocarcinoma
identifies KRAS mutant dosage as prognostic of overall survival.
Nat Med. 31:466–477. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cicenas J, Kvederaviciute K, Meskinyte I,
Meskinyte-Kausiliene E, Skeberdyte A and Cicenas J: KRAS, TP53,
CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer.
Cancers (Basel). 9:422017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Waddell N, Pajic M, Patch AM, Chang DK,
Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al:
Whole genomes redefine the mutational landscape of pancreatic
cancer. Nature. 518:495–501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim MK, Cho IR, Kim Y, Choi JH, Jung K,
Kim J, Kim S, Yun H, Yoon J, Oh DY, et al: Prognostic value of the
TP53 mutation in patients with pancreatic ductal adenocarcinoma
receiving FOLFIRINOX. Ther Adv Med Oncol. 16:175883592412904822024.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wong W, Raufi AG, Safyan RA, Bates SE and
Manji GA: BRCA mutations in pancreas cancer: Spectrum, current
management, challenges and future prospects. Cancer Manag Res.
12:2731–2742. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Katona BW, Lubinski J, Pal T, Huzarski T,
Foulkes WD, Moller P, Eisen A, Randall Armel S, Neuhausen SL, Raj
R, et al: The incidence of pancreatic cancer in women with a BRCA1
or BRCA2 mutation. Cancer. 131:e356662025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kowalewski A, Szylberg Ł, Saganek M,
Napiontek W, Antosik P and Grzanka D: Emerging strategies in
BRCA-positive pancreatic cancer. J Cancer Res Clin Oncol.
144:1503–1507. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng H, Liu C, Jiang J, Luo G, Lu Y, Jin
K, Guo M, Zhang Z, Xu J, Liu L, et al: Analysis of ctDNA to predict
prognosis and monitor treatment responses in metastatic pancreatic
cancer patients: Clinical value of ctDNA in metastatic pancreatic
cancer. Int J Cancer. 140:2344–2350. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mustafa M, Abbas K, Alam M, Habib S,
Zulfareen Hasan GM, Islam S, Shamsi A and Hassan I: Investigating
underlying molecular mechanisms, signaling pathways, emerging
therapeutic approaches in pancreatic cancer. Front Oncol.
14:14278022024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Waters AM and Der CJ: KRAS: The critical
driver and therapeutic target for pancreatic cancer. Cold Spring
Harb Perspect Med. 8:a0314352018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ye L, Fei Q, Li T, Lin C, Ou H, Zhang Y,
Zhou Y, Zhang J, Jin K, Yu X and Wu W: Genomic mutation and
clinicopathological features of KRAS wild-type tumors in Chinese
cohort with pancreatic adenocarcinoma. Genomics. 117:1110482025.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kent OA: Increased mutant KRAS gene dosage
drives pancreatic cancer progression: Evidence for wild-type KRAS
as a tumor suppressor? Hepatobiliary Surg Nutr. 7:403–405. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng DK, Oni TE, Thalappillil JS, Park Y,
Ting HC, Alagesan B, Prasad NV, Addison K, Rivera KD, Pappin DJ, et
al: Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type
RAS signaling in pancreatic cancer. Proc Natl Acad Sci USA.
118:e20169041182021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mouawad A, Habib S, Boutros M, Attieh F
and Kourie HR: How to find a needle in a haystack: A systematic
review on targeting KRAS wild-type pancreatic cancer. Future Oncol.
20:3539–3547. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shindo K, Yu J, Suenaga M, Fesharakizadeh
S, Cho C, Macgregor-Das A, Siddiqui A, Witmer PD, Tamura K, Song
TJ, et al: Deleterious germline mutations in patients with
apparently sporadic pancreatic adenocarcinoma. J Clin Oncol.
35:3382–3390. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Park JYP, Pacis A, Denroche RE,
Jang GH, Zhang A, Cuggia A, Domecq C, Monlong J, Raitses-Gurevich
M, et al: A preclinical trial and molecularly annotated patient
cohort identify predictive biomarkers in homologous
recombination-deficient pancreatic cancer. Clin Cancer Res.
26:5462–5476. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kindler HL, Hammel P, Reni M, Van Cutsem
E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et
al: Overall survival results from the POLO trial: A phase III study
of active maintenance olaparib versus placebo for germline
BRCA-mutated metastatic pancreatic cancer. J Clin Oncol.
40:3929–3939. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Witkiewicz AK, McMillan EA, Balaji U, Baek
G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, et
al: Whole-exome sequencing of pancreatic cancer defines genetic
diversity and therapeutic targets. Nature Commun. 6:67442015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee HS and Park SW: Systemic chemotherapy
in advanced pancreatic cancer. Gut Liver. 10:340–347. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schlick K, Kiem D and Greil R: Recent
advances in pancreatic cancer: Novel prognostic biomarkers and
targeted therapy-a review of the literature. Biomolecules.
11:14692021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma X, Liu X, Ou K, Zhang M, Gao L and Yang
L: Advanced pancreatic cancer with KRAS wild-type and
EGFR-sensitive mutation respond favorably to furmonertinib: A case
report. Front Oncol. 13:11511782023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Papa B, Dorwal P, Htain P, Robin J, Tan CP
and Singhal N: Acquired EGFR resistance mutation C797S in
pancreatic adenocarcinoma following partial response to
Third-Generation EGFR inhibitor therapy. JCO Precis Oncol.
8:e24001322024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qian Y, Gong Y, Fan Z, Luo G, Huang Q,
Deng S, Cheng H, Jin K, Ni Q, Yu X and Liu C: Molecular alterations
and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol
Oncol. 13:1302020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Y, Xu J, Zhang L, Song Y, Wen W, Lu
J, Zhao Z, Kong W, Liu W, Guo A, et al: A multicenter-retrospective
study of non-small-cell lung carcinoma harboring uncommon epidermal
growth factor receptor (EGFR) mutations: Different subtypes of EGFR
exon 19 deletion-insertions exhibit the clinical characteristics
and prognosis of non-small cell lung carcinoma. Transl Lung Cancer
Res. 11:238–249. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhuang W, Zhang C, Tang Y, Tian D, Lan Z,
Zeng C and Qiao G: Clinical and pathologic complete response to
gefitinib in a patient with SqCLC harboring EGFR p.E746_S752delinsV
mutation. Onco Targets Ther. 14:4805–4808. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pan M, Jiang C, Zhang Z, Achacoso N,
Alexeeff S, Solorzano AV, Tse P, Chung E, Sundaresan T, Suga JM, et
al: TP53 gain-of-function and non-gain-of-function mutations are
associated with differential prognosis in advanced pancreatic
ductal adenocarcinoma. JCO Precis Oncol. 7:e22005702023. View Article : Google Scholar : PubMed/NCBI
|
